Antimicrobial Therapy Guidelines

Introduction to Fluoroquinolones

The concurrent use of multiple fluoroquinolones is not recommended due to increased risk of adverse effects and toxicity, and is considered inappropriate antimicrobial practice 1
Using two fluoroquinolones simultaneously does not broaden antimicrobial coverage and increases the risk of class-specific adverse effects, violating principles of antimicrobial stewardship 1

For intra-abdominal infections, the European Society of Clinical Microbiology and Infectious Diseases recommends combination regimens of ciprofloxacin or levofloxacin and metronidazole 1
For skin infections, the Infectious Diseases Society of America recommends ceftriaxone or a fluoroquinolone (ciprofloxacin or levofloxacin) in combination with metronidazole 1
For respiratory infections, the European Respiratory Society recommends ciprofloxacin or β-lactam with P. aeruginosa activity ± aminoglycosides 2

Ciprofloxacin is preferred for Pseudomonas aeruginosa infections, according to the European Respiratory Society 2
Moxifloxacin is recommended for respiratory infections, including community-acquired pneumonia, by the Infectious Diseases Society of America 3
Moxifloxacin is effective as monotherapy in intra-abdominal infections, according to the International Society of Antimicrobial Chemotherapy 4

For respiratory tract infections, the Infectious Diseases Society of America recommends moxifloxacin 3
For Pseudomonas aeruginosa infections, the European Respiratory Society recommends ciprofloxacin with higher dosing of 750mg twice daily 2
For nontuberculous mycobacterial infections, the European Respiratory Society recommends moxifloxacin 5

For anaerobic coverage, the Infectious Diseases Society of America recommends adding metronidazole to ciprofloxacin 1, 4
For MDR tuberculosis, the American Thoracic Society recommends using either levofloxacin or moxifloxacin (not both) with other anti-TB drugs 6
The Infectious Diseases Society of America recommends that ciprofloxacin should only be used for urinary tract infections when the prevalence of resistance is known to be less than 10% 7
For enteric infections, the IDSA recommends that ciprofloxacin is only used when the organism is known to be susceptible 8
The IDSA suggests that fluoroquinolones should be reserved for important uses other than acute cystitis and considered alternative antimicrobials 7
When managing enteric fever with ciprofloxacin resistance, the IDSA recommends using ceftriaxone or azithromycin as alternative therapies 9, 1
For urinary tract infections, the IDSA recommends using trimethoprim-sulfamethoxazole if the organism is susceptible, or considering β-lactams as alternative therapies 7

Fluoroquinolones, including ciprofloxacin, should be avoided in pregnancy due to teratogenic effects, as recommended by the Centers for Disease Control and Prevention (CDC) 10
Using ciprofloxacin despite known resistance contributes to the growing problem of antimicrobial resistance, emphasizing the need for careful antibiotic selection and stewardship 7, 8, 9, 1
The safest approach when managing infections with multiple organisms showing different susceptibility patterns to ciprofloxacin is to select an alternative antibiotic that is effective against all organisms present, optimizing clinical outcomes and supporting antimicrobial stewardship efforts 7, 8, 9, 1